Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies

ανά De Buck, Stefan S, Jakab, Annamaria, Boehm, Markus, Bootle, Douglas, Juric, Dejan, Quadt, Cornelia, Goggin, Timothy K
Τόπος έκδοσης Br J Clin Pharmacol (2014)

A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors

ανά Toyoda, Masanori, Watanabe, Koichiro, Amagasaki, Taro, Natsume, Kazuto, Takeuchi, Hiromi, Quadt, Cornelia, Shirao, Kuniaki, Minami, Hironobu
Τόπος έκδοσης Cancer Chemother Pharmacol (2018)

Phase I study of alpelisib (BYL719), an α‐specific PI3K inhibitor, in Japanese patients with advanced solid tumors

ανά Ando, Yuichi, Iwasa, Satoru, Takahashi, Shunji, Saka, Hideo, Kakizume, Tomoyuki, Natsume, Kazuto, Suenaga, Naoko, Quadt, Cornelia, Yamada, Yasuhide
Τόπος έκδοσης Cancer Sci (2019)

Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors

ανά Ando, Yuichi, Inada-Inoue, Megumi, Mitsuma, Ayako, Yoshino, Takayuki, Ohtsu, Atsushi, Suenaga, Naoko, Sato, Masahiko, Kakizume, Tomoyuki, Robson, Matthew, Quadt, Cornelia, Doi, Toshihiko
Τόπος έκδοσης Cancer Sci (2014)

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

ανά Massacesi, Cristian, Di Tomaso, Emmanuelle, Urban, Patrick, Germa, Caroline, Quadt, Cornelia, Trandafir, Lucia, Aimone, Paola, Fretault, Nathalie, Dharan, Bharani, Tavorath, Ranjana, Hirawat, Samit
Τόπος έκδοσης Onco Targets Ther (2016)

NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models

ανά Jensen, Michael Rugaard, Schoepfer, Joseph, Radimerski, Thomas, Massey, Andrew, Guy, Chantale T, Brueggen, Josef, Quadt, Cornelia, Buckler, Alan, Cozens, Robert, Drysdale, Martin J, Garcia-Echeverria, Carlos, Chène, Patrick
Έκδοση 2008

The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth

ανά Garon, Edward B., Finn, Richard S., Hamidi, Habib, Dering, Judy, Pitts, Sharon, Kamranpour, Naeimeh, Desai, Amrita J., Hosmer, Wylie, Ide, Susan, Avsar, Emin, Jensen, Michael Rugaard, Quadt, Cornelia, Liu, Manway, Dubinett, Steven M., Slamon, Dennis J.
Έκδοση 2013

Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer: A Phase 1b Clinical Trial

ανά Juric, Dejan, Janku, Filip, Rodón, Jordi, Burris, Howard A., Mayer, Ingrid A., Schuler, Martin, Seggewiss-Bernhardt, Ruth, Gil-Martin, Marta, Middleton, Mark R., Baselga, José, Bootle, Douglas, Demanse, David, Blumenstein, Lars, Schumacher, Karl, Huang, Alan, Quadt, Cornelia, Rugo, Hope S.
Τόπος έκδοσης JAMA Oncol (2018)

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

ανά Juric, Dejan, Rodon, Jordi, Tabernero, Josep, Janku, Filip, Burris, Howard A., Schellens, Jan H.M., Middleton, Mark R., Berlin, Jordan, Schuler, Martin, Gil-Martin, Marta, Rugo, Hope S., Seggewiss-Bernhardt, Ruth, Huang, Alan, Bootle, Douglas, Demanse, David, Blumenstein, Lars, Coughlin, Christina, Quadt, Cornelia, Baselga, José
Τόπος έκδοσης J Clin Oncol (2018)

mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer

ανά Elkabets, Moshe, Vora, Sadhna, Juric, Dejan, Morse, Natasha, Mino-Kenudson, Mari, Muranen, Taru, Tao, Jessica, Campos, Ana Bosch, Rodon, Jordi, Ibrahim, Yasir H., Serra, Violeta, Rodrik-Outmezguine, Vanessa, Hazra, Saswati, Singh, Sharat, Kim, Phillip, Quadt, Cornelia, Liu, Manway, Huang, Alan, Rosen, Neal, Engelman, Jeffrey A., Scaltriti, Maurizio, Baselga, José
Έκδοση 2013

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer

ανά Rodon, Jordi, PérezFidalgo, Alejandro, Krop, Ian E., Burris, Howard, Guerrero-Zotano, Angel, Britten, Carolyn D., Becerra, Carlos, Schellens, Jan, Richards, Donald A., Schuler, Martin, Abu-Khalaf, Maysa, Johnson, Faye M., Ranson, Malcolm, Edenfield, Jeff, Silva, Antonio P., Hackl, Wolfgang, Quadt, Cornelia, Demanse, David, Duval, Vincent, Baselga, Jose
Τόπος έκδοσης Cancer Chemother Pharmacol (2018)

Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor

ανά Juric, Dejan, Castel, Pau, Griffith, Malachi, Griffith, Obi L., Won, Helen H., Ellis, Haley, Ebbesen, Saya H., Ainscough, Benjamin J., Ramu, Avinash, Iyer, Gopa, Shah, Ronak H., Huynh, Tiffany, Mino-Kenudson, Mari, Sgroi, Dennis, Isakoff, Steven, Thabet, Ashraf, Elamine, Leila, Solit, David B., Lowe, Scott W., Quadt, Cornelia, Peters, Malte, Derti, Adnan, Schegel, Robert, Huang, Alan, Mardis, Elaine R., Berger, Michael F., Baselga, José, Scaltriti., Maurizio
Τόπος έκδοσης Nature (2014)